Archives
- 2026-03
- 2026-02
- 2026-01
- 2025-12
- 2025-11
- 2025-10
- 2025-09
- 2025-03
- 2025-02
- 2025-01
- 2024-12
- 2024-11
- 2024-10
- 2024-09
- 2024-08
- 2024-07
- 2024-06
- 2024-05
- 2024-04
- 2024-03
- 2024-02
- 2024-01
- 2023-12
- 2023-11
- 2023-10
- 2023-09
- 2023-08
- 2023-07
- 2023-06
- 2023-05
- 2023-04
- 2023-03
- 2023-02
- 2023-01
- 2022-12
- 2022-11
- 2022-10
- 2022-09
- 2022-08
- 2022-07
- 2022-06
- 2022-05
- 2022-04
- 2022-03
- 2022-02
- 2022-01
- 2021-12
- 2021-11
- 2021-10
- 2021-09
- 2021-08
- 2021-07
- 2021-06
- 2021-05
- 2021-04
- 2021-03
- 2021-02
- 2021-01
- 2020-12
- 2020-11
- 2020-10
- 2020-09
- 2020-08
- 2020-07
- 2020-06
- 2020-05
- 2020-04
- 2020-03
- 2020-02
- 2020-01
- 2019-12
- 2019-11
- 2019-10
- 2019-09
- 2019-08
- 2019-07
- 2019-06
- 2019-05
- 2019-04
- 2018-07
-
br Introduction Soluble guanylyl cyclase GC maintains vascul
2022-05-18

Introduction Soluble guanylyl cyclase (GC-1) maintains vascular function through the NO/GC-1/cGMP pathway [1,2] by catalyzing the conversion of GTP into cGMP (Fig. 1). The GC-1 heme prosthetic group binds NO with picomolar affinity, resulting in a 100- to 200-fold increase in catalytic activity.
-
br The glycine transporter GlyT was
2022-05-18

The glycine transporter 1 (GlyT1) was originally identified as a member of the solute carrier family 6 of sodium- and chloride-dependent neurotransmitter transporters . GlyT1 is expressed in the central nervous system and in peripheral tissues; mainly in erythroid cells, from erythroblasts in the
-
Recognition and Repair of DNA Damage DNA is
2022-05-18

Recognition and Repair of DNA Damage DNA is a reactive molecule that is continually challenged by both endogenous and exogenous insults 1., 2.. Cellular metabolites and their byproducts, environmental toxins, and radiation alter the chemical structure of DNA, producing a wide spectrum of DNA damage
-
enolase Although we showed that RBL H Sc cells took up
2022-05-18

Although we showed that RBL-2H3 Sc98 enolase took up histamine from the microenvironment, it was unclear which transporter mediated its passage across the plasma membrane. Other biogenic amines have selective transporters that belong to the neurotransmitter sodium symporter family, including SERT f
-
BYL719 br Methods br Results and
2022-05-18

Methods Results and discussion Protein analysis of commonly used cell lines (C6, D54-MG, U87, U251 and STTG1) reveals high BYL719 of SXC (Cho and Bannai, 1990, Ye et al., 1999, de Groot et al., 2005, Lyons et al., 2007, Savaskan et al., 2008). Since protein expression can be altered over time
-
In glioma or glial derived primary brain tumors as
2022-05-18

In glioma, or glial-derived primary Selisistat tumors, as in other cancers, glutathione is an important survival mechanism. Glioma cells are dependent upon SXC-mediated cystine uptake for viability, as they require intracellular cystine/cysteine for GSH synthesis (Ogunrinu and Sontheimer, 2010, Sont
-
GK also called hexokinase IV or D is a
2022-05-18

GK, also called hexokinase IV or D, is a glycolytic enzyme that converts TCS 2002 australia to glucose-6-phosphate. GK has unique characteristics compared with those of the ubiquitously expressed hexokinase isoforms I–III, and is predominantly expressed in the pancreas and liver. In pancreatic β-cel
-
Yeast two hybrid screening studies have provided the
2022-05-18

Yeast two-hybrid screening studies have provided the foundation for countless investigations of protein-protein interactions [[141], [142], [143]]. To identify additional hepatic proteins similar to GKRP that are implicated in GCK regulation, a group of researchers conducted a two-hybrid study using
-
Staurosporine br Ghrelin actions in the central nervous
2022-05-18

Ghrelin actions in the central nervous system Ghrelin induces thymopoeisis GHS-R1a is expressed in immune cells, including thymocytes and T-cells [13]. Infusion of ghrelin increases the number of thymocytes and thymus size in 14-, 20-, and 24-month-old mice, and with decreased thymic adiposity
-
The snapshots in Fig were taken at the end of
2022-05-17

The snapshots in Fig. 5 were taken at the end of the first platteau i.e. for 5 Å rmsd or 4 ns time. Thus, we can see that the state of the i-motif affects the mechanism of the G-quadruplex unfolding. At acidic pH the stiff structure of the i-motif does not affect the bottom part (the innermost) of t
-
There are several basic science studies that aim
2022-05-17

There are several basic science studies that aim to investigate potential mechanisms behind the reduced incidence of MI in factor Xa inhibitor treated patients. Perzborn et al. reported that in-vitro addition of rivaroxaban reduced tissue-factor induced platelet aggregation (Perzborn, Heitmeier, & L
-
The VirScan assay has several advantages over alternative mu
2022-05-17

The VirScan assay has several advantages over alternative multiplex serological assays for peptide discovery. These advantages include quantitative assessment of antibody binding to peptides that span all open reading frames in the HIV genome, including both structural and regulatory proteins; repre
-
All of the designed compounds
2022-05-17

All of the designed compounds – was synthesized from -cyclopropane aldehyde , which was prepared following a procedure we reported previously. Treatment of with 4-chlorobenzene-1,2-diamine in pyridine constructed benzimidazole structure of , which was subjected to deprotection and subsequent oxidat
-
br ABT aR aR methyl hexahydropyrrolo b pyrrol yl
2022-05-17

ABT-288 (2-[4'-((3aR,6aR)-5-methyl-hexahydropyrrolo[3,4-b]pyrrol-1-yl)-biphenyl-4-yl]2H-pyridazine-3-one) is a selective H3R antagonist/inverse agonist developed by Abbott. Structurally, it is a compound with molecular weight (MW) 372.46 g/mol, three H-bond acceptors (HBA), and Moriguchi LogP (MLo
-
GSK has also been used as PET radiotracer in
2022-05-17

GSK-189254 has also been used as PET radiotracer (in the form of [11C]-GSK-189254, also used as [11C]-AZ12807110 by Jucaite et al. (Jucaite et al., 2013)) to assess H3R occupancy (Ashworth et al., 2010), and is currently used in an image-based phase I clinical trial study for investigating GSK-23951
16240 records 472/1083 page Previous Next First page 上5页 471472473474475 下5页 Last page